Veracyte, Inc.
VCYT
株式のランク
#4359
Veracyte, Inc. operates as a diagnostics company in the United States and... Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
株価
$44.93
最終同期: 2026-10-20
時価総額
$3.61B
変化（1日）
2.57%
変化（1年）
24.45%
国
US
取引 Veracyte, Inc. (VCYT)
カテゴリー
Healthcare
Veracyte, Inc.（VCYT）のP/B比率
October 2026 時点のP/B比率 TTM: 2.50
Veracyte, Inc. の最新の財務報告および株価によると、現在のP/B比率（TTM）は 2.50 です。2023 年末時点でのP/B比率は 1.91 でした。
Veracyte, Inc. の P/B 比率の履歴（2011 ～ 2026）
各年末時点のP/B比率
| 年 | P/B比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 2.50 | -3.24% |
| 2024 | 2.58 | 34.57% |
| 2023 | 1.91 | 21.21% |
| 2022 | 1.58 | -38.10% |
| 2021 | 2.55 | -58.76% |
| 2020 | 6.19 | 14.98% |
| 2019 | 5.38 | -7.87% |
| 2018 | 5.84 | -1.88% |
| 2017 | 5.95 | 58.90% |
| 2016 | 3.75 | 2.76% |
| 2015 | 3.64 | -27.86% |
| 2014 | 5.05 | 372.94% |
| 2013 | 1.07 | -97.22% |
| 2012 | 38.38 | 74.05% |
| 2011 | 22.05 | 0.00% |
同業他社のP/B比率
| 企業 | P/B比率 | P/B比率の差 | 国 |
|---|---|---|---|
| 4.7411 | 89.93% |
US
|
|
| 3.0143 | 20.75% |
US
|
|
| 31.051 | 1,143.88% |
US
|
|
| - | - |
CN
|
|
| 6.6641 | 166.96% |
US
|
